Pharmacology

Updated recommendations from the National Heart Foundation take into account the findings of recent meta-analyses, systematic reviews and randomised controlled trials

Genevieve M Gabb · Arduino A Mangoni · Craig S Anderson · Diane Cowley · John S Dowden · Jonathan Golledge · Graeme J Hankey · Faline S Howes · Les Leckie · Vlado Perkovic · Markus Schlaich · Nicholas A Zwar · Tanya L Medley · Leonard Arnolda

Supportive care encompasses managing symptoms and side effects before, during and after cancer treatment

Ian N Olver MB BS, MD, PhD

Potentially fatal dosing errors continue to occur despite a number of safety initiatives — new strategies are required

Rose Cairns PhD, BPharm(Hons) · Jared A Brown BPharm(Hons), MPH, FSHP · Ann-Maree Lynch BSc(Hons), PhD · Jeff Robinson BPharm, FSHP, GradDipHospPharm · Carol Wylie BPharm, PGDClinPharm · Nicholas A Buckley BMed, FRACP, MD

Systems approaches are needed to recognise the complexity of the biological bases of psychiatric disease

Philip M Boyce MB BS, MD, FRANZCP · Michael Berk PhD

Vigilance and clear guidelines for monitoring, regulation and education are needed

Conor C Hensey MB BCh, BAO · Amanda Gwee MB BS, FRACP, DTMH

Antidepressants are not as effective as we once believed

Christopher G Davey MB BS(Hons), PhD, FRANZCP · Andrew M Chanen MB BS(Hons), PhD, FRANZCP

Careful clinical selection of patients can help optimise the evidence-based use of opioids for chronic non-cancer pain

David C Currow PhD, FRACP, FAHMS · Jane Phillips PhD · Katherine Clark MMed, FRACP, FAChPM

MDR-TB threatens TB control programs in Australia’s region and will not diminish without concerted efforts

James M Trauer MPH, FRACP, FAFPHM · Allen C Cheng MPH, PhD, FRACP

Time to review the treatment guidelines in light of changing resistance patterns

Jeremy Brown MB BS, BMedSci · Simon J Willcox MPH(Hons), BCom · Neil Franklin MPH, BSc(Hons) · Briony Hazelton MPH · Matthew VN O'Sullivan PhD, FRACP, FRCPA

Summary of a consensus statement prepared by an expert panel on hepatitis C management with new direct-acting antiviral therapies

Alexander JV Thompson MB BS(Hons), PhD, FRACP

Putative allergies are common in older patients, but a significant proportion involve non-genuine allergies or low risk responses

Jason A Trubiano BBiomedSci, MB BS, FRACP · Rekha Pai Mangalore MB BS · Yi-Wei Baey MB BS(Hons) · Duy Le BPharm(Hons) · Linda V Graudins BPharm, DHP, PGDipClinEpi · Patrick GP Charles MB BS, PhD, FRACP · Douglas F Johnson MB BS, PhD, FRACP · Ar Kar Aung MB BS, FRACP, MPHTM

New strategies, and new antibiotics, are required to meet the challenge

Christine L Mandrawa MB BS · Katie Cronin MB BS(Hons) · Kirsty L Buising MPH, MD, FRACP · Yves S Poy Lorenzo BPharm · Mary J Waters MSc, MB BS, FRCPA · Cameron J Jeremiah MB BS, FRACP

Coordinated action on several fronts is required

John Turnidge MB BS, FRACP, FRCPA · Chris Baggoley FACEM, BMBS, BVSc · Mark Schipp BSc, BVMS · Robyn Martin BVMS, PhD

In addition to providing earlier access to more drugs, we need reform in how new cancer drugs are priced

Narcyz Ghinea BSc(Hons) · Wendy Lipworth MB BS, MSc, PhD

Australia needs new strategies for better asthma management

Tunn Ren Tay MB BS, MRCP · Michael J Abramson MB BS, PhD, FAFPHM · Mark Hew PhD, MScEBHC, FRACP

Careful assessment and universal precautions are necessary

Adrian J Dunlop PhD, GradDipEpiBiostat, FAChAM · Louise K Newman BA(Hons), MB BS(Hons), FRANZCP

Updated advice to be given by Triple Zero call-takers is being developed

Amy Kirwan BA(Hons), MSocSci, MSW · Michael Curtis BA, BSW(Hons) · Ingrid A van Beek MBA, FAFPHM, FAChAM · Kate Cantwell MEpi, PhD · Paul M Dietze PhD

Drug checking may need to play a part in future public health interventions

Robin J Butterfield MB BS, MRCA · Monica J Barratt BSc(Psych)(Hons), PhD · Nadine Ezard MB BS, PhD, FAChAM · Richard O Day MB BS (Hons), MD, FRACP

The TGA has changed naloxone scheduling to make it available over the counter

Simon R Lenton PhD, MPsych(Clin), BPsych · Paul M Dietze PhD · Marianne Jauncey BMed, MPH(Hons), FAFPHM

To be effective, a [monitoring program] must collect… prescription data, and flag potential misuse and diversion

Rowan P Ogeil PhD, BA, BSc(Hons) · Cherie Heilbronn MB BS, MPH · Belinda Lloyd PhD, BA(Hons) · Dan I Lubman PhD, FRANZCP, FAChAM